Posts tagged SGYP


With FDA Approvals in Sight, Will Synergy Pharmaceuticals and Agile Therapeutics Skyrocket as H.C Wainwright Predicts?

H.C. Wainwright spotlights 280% upside potential for Synergy and close to 111% upside potential for Agile ahead of FDA decisions.

Read more

Dmitry Balyasny Gets Bullish on 3 Drug Makers: Teva Pharmaceutical Industries Ltd (ADR) (TEVA), Synergy Pharmaceuticals Inc (SGYP), Opko Health Inc. (OPK)

Risk-taker Dmitry Balyasny eyes advantage in the biotech world, between new initiations in TEVA, SGYP, and a major increase in OPK.

Read more

Synergy Pharmaceutical (SGYP) on Sale Ahead of Upcoming PDUFA Date

Shares in gastrointestinal biopharma Synergy Pharmaceuticals Inc (NASDAQ:SGYP) are plunging by 30% this week, following the …

Read more

BTIG’s Take on Synergy Pharmaceuticals Inc (SGYP) and Transenterix Inc (TRXC)

Two healthcare companies with recently approved and much-hyped products- but which one makes a compelling …

Read more

Synergy Pharmaceuticals Inc (SGYP): Analyst Makes Bullish Case for Robust Value in Trulance Asset

Canaccord forecasts DTC marketing could be big for SGYP’s Trulance next year, in footsteps of rival Linzess.

Read more

Synergy Pharmaceuticals Inc (SGYP): A 2018 Story Shapes Up

By Bret Jensen Small biotech stocks especially ‘Tier 3‘ concerns like Omeros and Flexion Therapeutics have …

Read more

H.C. Wainwright Pounds the Table on Synergy Pharmaceuticals Inc (SGYP)

H.C. Wainwright analyst Ram Selvaraju was out pounding the table on shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) …

Read more

Synergy Pharmaceuticals Inc’s (SGYP) Trulance Launch Just Keeps Getting Better

H.C. Wainwright predicts the CIC drug’s annualized run rate surpasses $30 million.

Read more

Oppenheimer Casts 3Q Predictions: Teva Pharmaceutical Industries Ltd (ADR) (TEVA), Synergy Pharmaceuticals Inc (SGYP)

Derek Archila thinking twice before ready to bet on Teva’s turnaround, but Synergy could bring some upside.

Read more

Here’s Why H.C. Wainwright Just Cut the Price Target for Synergy Pharmaceuticals Inc (SGYP) by 50%

Ram Selvaraju slashes his target to $8 on slower Trulance ramp.

Read more